Table 2. Sensitivity Analyses for Comparison of SGLT2 Inhibitors and Sulfonylureas as Reference Group on Risk of All-Cause Mortality.
| Sensitivity analyses | Hazard ratio | Death rate per 1000 person-years (adjusted 95% CI) | Event reduction per 1000 person-years (95% CI) | |
|---|---|---|---|---|
| SGLT2 inhibitors | Sulfonylureas | |||
| Censored on February 29, 2020 | 0.82 (0.74 to 0.91) | 20.84 (18.85 to 22.72) | 25.11 (23.85 to 26.77) | −4.47 (−6.63 to −2.42) |
| Inverse probability treatment weight | 0.87 (0.77 to 0.99) | 22.19 (19.65 to 24.89) | 25.49 (24.82 to 26.23) | −3.32 (−5.97 to −0.32) |
| Propensity score–based on LASSO regression | 0.79 (0.74 to 0.85) | 22.86 (21.32 to 24.60) | 28.69 (27.49 to 29.77) | −5.78 (−7.89 to −3.56) |
| Within patients enrolled in 2016 and 2017 | 0.88 (0.77 to 0.99) | 25.20 (22.22 to 28.22) | 28.33 (26.40 to 30.37) | −3.12 (−3.08 to −0.21) |
| Within patients enrolled in 2018, 2019, and 2020 | 0.77 (0.70 to 0.85) | 21.44 (19.46 to 23.13) | 27.36 (25.91 to 29.07) | −5.82 (−8.07 to −3.96) |
| Excluded patients with events within 180 d from treatment initiationa | 0.82 (0.76 to 0.88) | 20.80 (19.43 to 22.25) | 24.68 (23.74 to 25.86) | −3.94 (−5.49 to −2.31) |
| Excluded patients with events within 90 d from treatment initiationb | 0.84 (0.78 to 0.91) | 22.05 (20.60 to 23.49) | 26.69 (25.67 to 27.81) | −4.71 (−6.40 to −2.73) |
Abbreviations: LASSO, least absolute shrinkage and selection operator; SGLT2, sodium-glucose cotransporter 2.
a
A total of 181 (18.81%) of the events from the SGLT2 inhibitor group and 1098 (14.04%) of the events from the sulfonylurea group were excluded.
b
A total of 85 (9.96%) of the events from the SGLT2 inhibitor group and 502 (6.42%) of the events from the sulfonylurea group were excluded.